Objective:To study the nutritional status and inflammatory stress levels after gastric cancer patients with chemotherapy received palonosetron and tropisetron.Methods: 94 patients with advanced gastric cancer undergoi...Objective:To study the nutritional status and inflammatory stress levels after gastric cancer patients with chemotherapy received palonosetron and tropisetron.Methods: 94 patients with advanced gastric cancer undergoing FOLFOX4 intravenous chemotherapy in our hospital between May 2014 and March 2016 were selected and randomly divided into observation group (n=47) and control group (n=47) who received palonosetron and tropisetron for chemotherapy anti-emesis respectively. After four cycles of chemotherapy, serum samples were collected from two groups of patients to determine nutritional status, inflammatory reaction and stress reaction indexes.Results:After four cycles of chemotherapy, serum albumin (ALB), prealbumin (PAB), transferrin (TFN), immunoglobulin A (IgA), IgG and IgM content of observation group were significantly higher than those of control group (P<0.05). After four cycles of chemotherapy, serum Keap1 content of observation group was significantly higher than that of control group (P<0.05), while Nrf2, ARE, NQO1, HO-1, interferon-γ (IFN-γ), tumor necrosis factorα (TNF-α), interleukin-4 (IL-4) and IL-10 content were significantly lower than those of control group (P<0.05).Conclusions:Palonosetron has better antiemetic effect than tropisetron for gastric cancer patients with chemotherapy, and after chemotherapy, the nutritional status is better and the inflammatory stress level is lighter.展开更多
Extracellular amyloid beta(Aβ) plaques are main pathological feature of Alzheimer’s disease.However,the specific type of neuro ns that produce Aβ peptides in the initial stage of Alzheimer’s disease are unknown.In...Extracellular amyloid beta(Aβ) plaques are main pathological feature of Alzheimer’s disease.However,the specific type of neuro ns that produce Aβ peptides in the initial stage of Alzheimer’s disease are unknown.In this study,we found that 5-hydroxytryptamin receptor 3A subunit(HTR3A) was highly expressed in the brain tissue of transgenic amyloid precursor protein and presenilin-1 mice(an Alzheimer’s disease model) and patients with Alzheimer’s disease.To investigate whether HTR3A-positive interneurons are associated with the production of Aβ plaques,we performed double immunostaining and found that HTR3A-positive interneurons were clustered around Aβ plaques in the mouse model.Some amyloid precursor protein-positive or β-site amyloid precursor protein cleaving enzyme-1-positive neurites near Aβ plaques were co-localized with HTR3A interneurons.These results suggest that HTR3A-positive interneurons may partially contribute to the generation of Aβ peptides.We treated 5.0-5.5-month-old model mice with tro pisetron,a HTR3 antagonist,for 8 consecutive weeks.We found that the cognitive deficit of mice was partially reversed,Aβ plaques and neuroinflammation we re remarkably reduced,the expression of HTR3 was remarkably decreased and the calcineurin/nuclear factor of activated T-cell 4 signaling pathway was inhibited in treated model mice.These findings suggest that HTR3A interneurons partly contribute to generation of Aβ peptide at the initial stage of Alzheimer’s disease and inhibiting HTR3 partly reve rses the pathological changes of Alzheimer’s disease.展开更多
目的比较托烷司琼和艾司奥美拉唑对结直肠癌患者化疗相关胃肠道不良反应的防治效果。方法选取2020年1月至2022年1月南阳市第一人民医院收治的124例结直肠癌化疗患者进行随机对照试验。采用抽签法将其分为A组和B组,各62例。A组男32例,女3...目的比较托烷司琼和艾司奥美拉唑对结直肠癌患者化疗相关胃肠道不良反应的防治效果。方法选取2020年1月至2022年1月南阳市第一人民医院收治的124例结直肠癌化疗患者进行随机对照试验。采用抽签法将其分为A组和B组,各62例。A组男32例,女30例,年龄(55.25±5.37)岁。B组男31例,女31例,年龄(56.07±5.22)岁。A组应用托烷司琼配合化疗,B组应用艾司奥美拉唑配合化疗。两组均随访1年。比较两组患者化疗期间胃肠道不良反应发生情况,化疗第1、7、14天时以及1个化疗周期后恶心呕吐干呕症状评估量表(Index of Nausea,Vomiting,and Retching,INVR)评分以及远期生存质量。采用χ^(2)检验和t检验。结果经不同药物配合治疗后,A组化疗期间胃肠道不良反应发生率、反酸频率、恶心频率、呕吐频率均低于B组[12.90%(8/62)比30.65%(19/62)、(1.16±0.23)次/d比(3.44±1.22)次/d、(2.14±0.45)次/d比(4.41±1.23)次/d、(1.27±0.33)次/d比(3.11±1.25)次/d;χ^(2)=5.729,t=14.461、13.647、11.207,均P<0.05]。A组化疗第1天INVR评分(20.33±5.41)分,B组(21.24±5.18)分,差异无统计学意义(t=1.272,P>0.05);A组化疗第7、14天和化疗1个周期时INVR评分均低于B组[(15.11±3.46)分比(18.61±3.12)分、(12.33±2.46)分比(14.24±3.36)分、(10.19±1.47)分比(12.25±2.72)分;t=5.915、5.156、5.246,均P<0.05]。随访期间,A组结直肠癌患者生命质量测定量表(Functional Assessment of Cancer Therapy of Colorectal,FACT-C)中生理状况、社会/家庭状况、情感状况、功能状况、睡眠状况、依从状况维度评分均高于B组[(22.45±5.33)分比(19.35±5.31)分、(23.36±5.27)分比(20.18±5.32)分、(20.31±5.24)分比(17.25±5.33)分、(21.25±5.16)分比(18.44±5.28)分、(23.11±5.17)分比(20.21±5.22)分、(23.35±5.25)分比(20.22±5.32)分;t=3.244、3.344、3.244、2.997、3.108、3.297,均P<0.05]。结论托烷司琼对胃肠道不良反应的防治效果均优于艾司奥美拉唑。展开更多
背景与目的:5-羟色胺3(5-hydroxytryptamine3,5-HT3)受体阻断剂是临床最常用的化疗药物所致恶心、呕吐的预防治疗药,盐酸托烷司琼作为高效的5-HT3受体选择性阻断剂,已在临床应用多年。本试验目的在于评价国产盐酸托烷司琼注射液防治顺...背景与目的:5-羟色胺3(5-hydroxytryptamine3,5-HT3)受体阻断剂是临床最常用的化疗药物所致恶心、呕吐的预防治疗药,盐酸托烷司琼作为高效的5-HT3受体选择性阻断剂,已在临床应用多年。本试验目的在于评价国产盐酸托烷司琼注射液防治顺铂等化疗药物所致患者消化道反应的疗效及安全性。方法:本研究采用双盲、阳性药物交叉对照的方法,将5家医院收治的、需顺铂化疗的肿瘤患者随机分为A-B和B-A组,分别用试验药或对照药治疗。结果:共118例患者入组,其中A-B组60例,B-A组58例。国产盐酸托烷司琼和进口盐酸托烷司琼用药后患者急性呕吐的程度没有差异(P>0.05);两组对化疗药物所致恶心的平均抑制率分别为28.59%和29.21%;呕吐的平均抑制率分别为52.61%和51.94%;以上结果差异均无统计学意义(P>0.05)。用药后第3、6、10、21天生活质量(quality of life,QOL)评分两药差异没有统计学意义(P>0.05)。两药不良反应发生率分别为27.97%和22.03%,主要包括便秘、腹胀、眩晕、头痛和疲劳等,差异无统计学意义(P>0.05)。结论:国产盐酸托烷司琼注射液治疗顺铂等化疗药物所致急性和迟发性恶心、呕吐反应疗效可靠,而且维持时间长,不良反应较少,对患者生活质量也有改善,各项临床试验指标与进口盐酸托烷司琼相似。展开更多
文摘Objective:To study the nutritional status and inflammatory stress levels after gastric cancer patients with chemotherapy received palonosetron and tropisetron.Methods: 94 patients with advanced gastric cancer undergoing FOLFOX4 intravenous chemotherapy in our hospital between May 2014 and March 2016 were selected and randomly divided into observation group (n=47) and control group (n=47) who received palonosetron and tropisetron for chemotherapy anti-emesis respectively. After four cycles of chemotherapy, serum samples were collected from two groups of patients to determine nutritional status, inflammatory reaction and stress reaction indexes.Results:After four cycles of chemotherapy, serum albumin (ALB), prealbumin (PAB), transferrin (TFN), immunoglobulin A (IgA), IgG and IgM content of observation group were significantly higher than those of control group (P<0.05). After four cycles of chemotherapy, serum Keap1 content of observation group was significantly higher than that of control group (P<0.05), while Nrf2, ARE, NQO1, HO-1, interferon-γ (IFN-γ), tumor necrosis factorα (TNF-α), interleukin-4 (IL-4) and IL-10 content were significantly lower than those of control group (P<0.05).Conclusions:Palonosetron has better antiemetic effect than tropisetron for gastric cancer patients with chemotherapy, and after chemotherapy, the nutritional status is better and the inflammatory stress level is lighter.
基金supported by the Notional Natural Science Foundation of China,Nos.81371213 and 8107098 7the Natural Science Foundation of Shanghai,No.21ZR1468400 (all to QLY)。
文摘Extracellular amyloid beta(Aβ) plaques are main pathological feature of Alzheimer’s disease.However,the specific type of neuro ns that produce Aβ peptides in the initial stage of Alzheimer’s disease are unknown.In this study,we found that 5-hydroxytryptamin receptor 3A subunit(HTR3A) was highly expressed in the brain tissue of transgenic amyloid precursor protein and presenilin-1 mice(an Alzheimer’s disease model) and patients with Alzheimer’s disease.To investigate whether HTR3A-positive interneurons are associated with the production of Aβ plaques,we performed double immunostaining and found that HTR3A-positive interneurons were clustered around Aβ plaques in the mouse model.Some amyloid precursor protein-positive or β-site amyloid precursor protein cleaving enzyme-1-positive neurites near Aβ plaques were co-localized with HTR3A interneurons.These results suggest that HTR3A-positive interneurons may partially contribute to the generation of Aβ peptides.We treated 5.0-5.5-month-old model mice with tro pisetron,a HTR3 antagonist,for 8 consecutive weeks.We found that the cognitive deficit of mice was partially reversed,Aβ plaques and neuroinflammation we re remarkably reduced,the expression of HTR3 was remarkably decreased and the calcineurin/nuclear factor of activated T-cell 4 signaling pathway was inhibited in treated model mice.These findings suggest that HTR3A interneurons partly contribute to generation of Aβ peptide at the initial stage of Alzheimer’s disease and inhibiting HTR3 partly reve rses the pathological changes of Alzheimer’s disease.
文摘目的比较托烷司琼和艾司奥美拉唑对结直肠癌患者化疗相关胃肠道不良反应的防治效果。方法选取2020年1月至2022年1月南阳市第一人民医院收治的124例结直肠癌化疗患者进行随机对照试验。采用抽签法将其分为A组和B组,各62例。A组男32例,女30例,年龄(55.25±5.37)岁。B组男31例,女31例,年龄(56.07±5.22)岁。A组应用托烷司琼配合化疗,B组应用艾司奥美拉唑配合化疗。两组均随访1年。比较两组患者化疗期间胃肠道不良反应发生情况,化疗第1、7、14天时以及1个化疗周期后恶心呕吐干呕症状评估量表(Index of Nausea,Vomiting,and Retching,INVR)评分以及远期生存质量。采用χ^(2)检验和t检验。结果经不同药物配合治疗后,A组化疗期间胃肠道不良反应发生率、反酸频率、恶心频率、呕吐频率均低于B组[12.90%(8/62)比30.65%(19/62)、(1.16±0.23)次/d比(3.44±1.22)次/d、(2.14±0.45)次/d比(4.41±1.23)次/d、(1.27±0.33)次/d比(3.11±1.25)次/d;χ^(2)=5.729,t=14.461、13.647、11.207,均P<0.05]。A组化疗第1天INVR评分(20.33±5.41)分,B组(21.24±5.18)分,差异无统计学意义(t=1.272,P>0.05);A组化疗第7、14天和化疗1个周期时INVR评分均低于B组[(15.11±3.46)分比(18.61±3.12)分、(12.33±2.46)分比(14.24±3.36)分、(10.19±1.47)分比(12.25±2.72)分;t=5.915、5.156、5.246,均P<0.05]。随访期间,A组结直肠癌患者生命质量测定量表(Functional Assessment of Cancer Therapy of Colorectal,FACT-C)中生理状况、社会/家庭状况、情感状况、功能状况、睡眠状况、依从状况维度评分均高于B组[(22.45±5.33)分比(19.35±5.31)分、(23.36±5.27)分比(20.18±5.32)分、(20.31±5.24)分比(17.25±5.33)分、(21.25±5.16)分比(18.44±5.28)分、(23.11±5.17)分比(20.21±5.22)分、(23.35±5.25)分比(20.22±5.32)分;t=3.244、3.344、3.244、2.997、3.108、3.297,均P<0.05]。结论托烷司琼对胃肠道不良反应的防治效果均优于艾司奥美拉唑。
文摘背景与目的:5-羟色胺3(5-hydroxytryptamine3,5-HT3)受体阻断剂是临床最常用的化疗药物所致恶心、呕吐的预防治疗药,盐酸托烷司琼作为高效的5-HT3受体选择性阻断剂,已在临床应用多年。本试验目的在于评价国产盐酸托烷司琼注射液防治顺铂等化疗药物所致患者消化道反应的疗效及安全性。方法:本研究采用双盲、阳性药物交叉对照的方法,将5家医院收治的、需顺铂化疗的肿瘤患者随机分为A-B和B-A组,分别用试验药或对照药治疗。结果:共118例患者入组,其中A-B组60例,B-A组58例。国产盐酸托烷司琼和进口盐酸托烷司琼用药后患者急性呕吐的程度没有差异(P>0.05);两组对化疗药物所致恶心的平均抑制率分别为28.59%和29.21%;呕吐的平均抑制率分别为52.61%和51.94%;以上结果差异均无统计学意义(P>0.05)。用药后第3、6、10、21天生活质量(quality of life,QOL)评分两药差异没有统计学意义(P>0.05)。两药不良反应发生率分别为27.97%和22.03%,主要包括便秘、腹胀、眩晕、头痛和疲劳等,差异无统计学意义(P>0.05)。结论:国产盐酸托烷司琼注射液治疗顺铂等化疗药物所致急性和迟发性恶心、呕吐反应疗效可靠,而且维持时间长,不良反应较少,对患者生活质量也有改善,各项临床试验指标与进口盐酸托烷司琼相似。
